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INTRODUCTION
Fungal foot infection (FFI) continues to be the most commonly
encountered infection on the foot. Rarely a threat to life, it still
remains a cause of morbidity and quality of life, particularly when
affecting the nails.1-3 Around 34% of the European population is
thought to have FFI (as tinea pedis, onychomycosis or both).4
Regional variation is apparent, with rates generally higher in
Northern areas, probably because of longer winters, necessitating
the wearing of occlusive footwear for longer periods of the year,
promoting fungal growth. Infection rates are also higher in males
and increase with age.5
The main causative agents are a group of fungi adapted to
living on the keratin of skin – the dermatophytes. The most
frequent agents responsible for fungal foot infection remain
Trichophyton rubrum and, to a lesser extent, T. mentagrophytes var.
interdigitale, which between them made up around 90% of fungal
foot infections in the UK in 2005.6
Fungal elements are acquired from the ground, where they may
lie dormant for long periods. Fungal spores then may attach and
adhere to the stratum corneum,7 and begin to germinate within 24
hours if optimum conditions are present.8 For many patients the
typical dermatophyte infection with T. rubrum remains silent and is
often unnoticed by the sufferer,9 leading to chronicity of the
condition.
Fungal infection can reside on the plantar surface before
spreading to the interdigital areas and eventually into the nails,
where it can act as a protected source for further infection to other
parts of the body.10 Fungal nail infection rates are estimated to be
around 8%.11 However, like tinea pedis, infection rates increase
with age12 and are seen most frequently in the over 50s.13 Nails
that have been damaged are particularly susceptible to fungal
invasion.
DIAGNOSIS OF FUNGAL FOOT INFECTION
Establishing a diagnosis remains an important step in the
management of FFI, particularly if an oral drug is to be prescribed.
Mycological evaluation is the most commonly used approach to
establish the presence and identification of a pathogen in a sample
of skin or nail. Practitioners are often frustrated by negative
mycological results returned from the laboratory despite the
clinical appearance of mycotic disease. In part, the success of the
mycology relies on the skill of the practitioner taking the specimen
and of the laboratory technician being able to process and visualise
any viable fungal elements.
Firstly, studies have shown that, with typical distal and lateral
onychomycosis, successful retrieval of fungus and ultimately a
mycologically positive result is established by taking a nail sample
as proximal as possible to the advancing fungal edge. In the studies
conducted by Shemer and colleagues,14 the more proximal the
sample, the higher the yield rate, particularly if vertical drilling of
Figure 1. Plantar T. rubrum infection
Continuing
Professional Development
CPD.qxp:Layout 1 14/11/14  13:04  Page 1
the nail plate was incorporated15 to help access and extract
sub-ungual debris when compared with a distal nail clipping.
KEY POINT
When taking a nail sample for mycology testing, the more proximal the
sample, the higher the chance of a positive diagnosis in distal fungal nail
infection.
When a sample is being taken, adequate amounts must be sent
to the laboratory to maximise the chances of a correct, positive
diagnosis. Unlike bacterial swabs, fungal clippings do not need to
be sent to the laboratory the same day. Delay causes drying in the
sample, which does not affect the viability of the fungus but does
kill any contaminant bacteria present. Once under the microscope
and treated with potassium hydroxide (KOH), the skill of the
operator is important to be able to locate and visualise fungal
elements on the sample to give the diagnosis. These results can be
available rapidly but the culturing of a sample on a Petri-dish can
take up to several weeks.
New developments in the diagnosis of fungal foot
infection
The shortcomings of these standard techniques have been noted,
and alternative methods are now slowly being introduced. The
Periodic-Acid Schiff (PAS) stain is a staining method that detects
the presence of glycogen and other polysaccharides (glycoproteins
and glycolipids) in tissues and can be rapidly performed. It has a
range of applications in medicine but as fungal elements have a
concentration of these products in their membrane, it has
diagnostic potential in fungal infection.
Studies to confirm the effectiveness of the PAS technique have
been undertaken. Compared with mycology, PAS consistently had
a higher sensitivity in visualising fungal elements in samples than
KOH and microscopy techniques.16,17 Lawry18 found PAS to be 85%
sensitive compared with 57% for KOH microscopy, whilst a 2010
study found PAS 88% sensitive versus 50% for microscopy.19 This
may appear to be a future gold standard, as PAS is able to improve
significantly the detection of fungal elements. However, it does not
allow for identification of the specific species and occasionally
false positives can be yielded when starch is present in the sample,
such as with psoriatic nails,20 and so culture still remains an
important step in the process. In addition, a PAS stain costs around
three times as much as fungal microscopy and culture.
Polymerase Chain Reaction techniques
Recognising the advantages of the PAS stain and its shortcomings,
research has sought to develop a new technique that can
demonstrate the presence of fungus consistently and identify the
species, all in a timeframe much lower than the three weeks for
culture. Polymerase Chain Reaction (PCR) is a molecular biological
technology that can amplify sample fragments of DNA into many
thousands of exact copies, permitting identification. The technique
has been employed since the early 1980s and is used in paternity
testing, forensic sciences and infectious diseases. Research to date
in mycology has demonstrated this technique to have high
sensitivities and specificities compared with traditional microscopy
and cultures – in essence, showing itself to be a more rapid and
reliable technique.21 Most recently, a method has been reported
giving a rapidly reliable turnaround directed at identifying the
presence of dermatophyte species only.22 Further developments are
occurring and in the future, this may become a laboratory standard
test.
DRUG TREATMENTS IN FUNGAL FOOT INFECTION
Topical agents for tinea pedis
Tinea pedis is a condition that is generally amenable to topical
antifungal agents. In the UK today, most topical skin preparations
are available from pharmacies without a prescription. A summary
of the common preparations is presented in Table 1. These may be
available in a range of vehicles depending on the individual
products such as creams, gels, sprays etc. Some (marked with an
asterisk) may also be available as non-proprietary (generic) brands
and so may be cheaper for the patient to purchase.
The differences in the efficacy of topical treatments for tinea
pedis have been explored. In a Cochrane review of 67 trials of
topical treatments for tinea pedis, it was concluded that
allylamines (terbinafine) and the azole group (miconazole,
clotrimazole, etc) were much more effective than placebo. Head-
to-head, allylamines (terbinafine) produced a slightly higher cure
rate than the azoles23 with a faster time to cure. In a more recent
meta-analysis, a similar conclusion was reached but the superiority
of terbinafine over the azoles was emphasised.24 Topical
terbinafine preparations remain more expensive than topical azole
drugs, though the recent introduction of generic terbinafine
products may reduce the over-the-counter costs.
In recent years, a single topical treatment for tinea pedis has
been developed and introduced (as Lamisil Once®). A number of
studies have concluded this to be comparable in efficacy to the
traditional terbinafine cream, when used as directed.25,26 A large
scale review of terbinafine in its various forms and preparations
was undertaken and concluded that the drug is equally effective in
the various formulations in the topical treatment of tinea pedis.27
KEY POINT
Topical terbinafine has been shown to be equally effective for treating
tinea pedis in all its forms, such as a spray, cream and film-forming
solution.
Based on the available evidence to date, other treatments such
as tolnaftate, undecenoates and older preparations such as
Whitfield’s ointment (benzoic and salicylic acid) are probably less
effective than azoles and terbinafine. Tea tree oil (Melaleuca)
remains a popular over-the-counter treatment based on its
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Tolnaftate Scholl Athletes Foot Treatment®, Mycil*
* may also be available as non-proprietary (generic) products
Table 1. Topical preparations available for the treatment of tinea
pedis in the UK
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antifungal properties. Although it has shown potential for use in
interdigital tinea pedis, its propensity to cause irritancy and allergy
remains an issue.28,29 In the original study for the treatment of
tinea pedis using the oil, 3.8% of subjects developed dermatitis.30
Whilst it is appreciated that tea tree oil represents a heterogeneous
group of formulations with differing properties, the available
licensed topical antifungal preparations hold a significantly lower
risk of irritancy and so the practitioner should consider this with
the along with the needs of the patient before recommending.
KEY POINT
The use of tea tree oil in the treatment of onychomycosis is not
recommended by National Institute for Health and Care Excellence (NICE)
guidelines.
Emerging topical drugs in the treatment of fungal foot
infection
As there is a desire to reduce risk to patients undergoing antifungal
therapy, much development work has focused on new topical
agents, to avoid the risks associated with systemic drugs.
Traditionally, the difficulty for topical products applied to the nail
has been the nail thickness and the fact that nail keratin binds
many drugs, reducing the amount of free drug reaching the deeper
areas of the nail plate. Pharmacological research has focussed on
agents that can penetrate the nail plate more effectively. To this
end, two new products have recently been developed, licensed and
marketed in the USA and Japan. Luliconazole (Luzu 1% cream®
and a topical nail solution) is a newer topical antifungal agent that
has been licensed as a cream and solution. Although an imidazole,
studies have shown its activity and potency against the common
dermatophytes to be similar or superior to terbinafine, with
improved drug delivery as it does not bind so readily to keratin
compared with other imidazoles.31
Efinaconazole has also been recently licensed in the USA and
Japan. A triazole agent, similar to itraconazole, this is currently
marketed as a solution for the topical treatment of onychomycosis,
and, like Luliconazole, it has a broad spectrum against a range of
dermatophyte and non-dermatophyte moulds and does not bind to
keratin, making more of the drug available for delivery through the
nail.32 Further work is ongoing to investigate these new products.
These drugs are not currently available in the UK at the time of
writing.
Topical agents for onychomycosis
When onychomycosis is considered to be mild to moderate
(essentially sparing the lunula), topical agents can be considered
although treatment requires good compliance as it can continue for
6-12 months. In the UK, there are two drugs available. Amorolfine
5% is a nail lacquer applied to the affected nails once or twice a
week. It is available as a prescription only medicine (POM;
Loceryl® Lacquer – 5 ml) and as a generic drug. Smaller quantities
can be purchased by patients at pharmacies under the brand name
Curanail® (3 ml). Tioconazole 28% is also a POM nail paint
(Trosyl®) applied daily to the affected nails. Recommendations
published on the use on topical antifungals suggest amorolfine to
be a superior agent with cure rates of around 50%,33 and so should
be considered as the first-line choice of treatment in mild-to-
moderate nail disease.
Studies have proven that the delivery of topical drugs to the
infected nail can be enhanced by reducing the nail.34-36 This should
be considered as standard practice before commencing antifungal
therapy. However, drilling nails has raised concerns about the
hazards of nail dust.37 Alternative techniques using a chemical
avulsion consisting of 40% urea applied to the nail have shown
success when compared with topical treatment without urea
avulsion.38 A proprietary formulation of 40% urea fungal treatment
is now available in the UK as an over-the-counter product for home
use by patients (Canespro®). The cost is around £30. As the
product only contains urea, an additional topical antifungal will
need to be used with it, increasing the cost to the patient.
Moreover, it is important to note that a 40% urea ointment will
only dissolve nail that is infected and leave healthy nail intact.
Therefore, the product should only be used where the nail is
dystrophic through the whole thickness of the nail plate (ventral to
dorsal), as sub-ungual infection underneath a relatively healthy
nail will not respond to this therapy.
KEY POINT
Nail reduction prior to antifungal treatment in onychomycosis improves the
cure rate.
A range of non-pharmacological treatments is available to
patients such as Phytex® Paint (Borotannic complex 8%), Excilor®
(Ethyllactate and acetic acid) and generic antifungal nail solutions,
although published studies on these agents remain limited. Current
guidelines from NICE do not recommend tea tree oil for the
treatment of onychomycosis.39
Systemic drugs
Systemic antifungal agents are indicated in the treatment of both
tinea pedis and onychomycosis, although rarely are they prescribed
for the former, as topical agents are generally sufficient in most
patients. The decision to treat toenail onychomycosis with a
systemic agent should be considered carefully, and the following
criteria are suggested as a guide to proceed with treatment:39
 Walking is uncomfortable.
 Abnormal-looking nails are causing significant psychological
distress.
 The person has diabetes, vascular disease, or a connective tissue
disorder (because of a higher risk for secondary bacterial
infections and cellulitis).
 The nail infection is thought to be the source of fungal skin
infection.
 The person is, or likely to become, severely immunocompromised
(for example with haematological malignancy or its treatment).
Figure 2. Onycomycosis
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Every patient receiving an oral antifungal agent should have a
positive confirmation of the diagnosis prior to commencement to
prevent inappropriate therapy. Terbinafine is recommended as the
first-line drug of choice for onychomycosis, particularly when the
infection is considered severe (where infection has spread to the
lunula and deeper into the nail matrix). The drug is given as a
250mg dose (3-6 months with a visible improvement normally
expected after three months in new nail growth). As an alternative,
itraconazole can also be used (usually as pulse treatment - 200mg
b.d. for one week then repeated after 21 days). At least three
pulses in toenail infections are normally recommended. Meta-
analysis of published studies has shown terbinafine to be more
effective than itraconazole,40,41 with fewer side-effects and
interactions.
KEY POINT
Any patient receiving systemic antifungal agents should first have the
infection confirmed in the laboratory to prevent prescribing errors.
When discussing systemic antifungal agents, safety is often a
concern. Shortly after the launch of terbinafine, a case of liver
toxicity was reported, raising concerns about its safety. Subsequent
studies have consistently shown the drug to have a low incidence
of adverse effects.42-44 Typically, these have been mild and transient
such as taste disturbance, nausea, abdominal pain and diarrhoea.
However, systemic agents should generally be avoided in those
with known liver disorders.
Griseofulvin is an older oral antifungal drug that has shown to
be effective in dermatophyte nail infections. As its effectiveness is
less than half that of the newer agents such as terbinafine, its use
should be reserved for those who cannot take the first-line drugs,
although outcomes with griseofulvin are likely to be significantly
poorer.45 It should not be used to treat onychomycosis caused by
non-dermatophyte moulds due to its limited spectrum of activity.
Other systemic agents such as fluconazole and ketoconazole,
although unlicensed for the treatment of onychomycosis, have
been used. However, oral ketoconazole (Nizoral®) has been
suspended by the European Medicines Agency due to the high risks
of liver toxicity associated with this drug and the availability of
safer alternatives in the management of fungal nail infection.46
Although onychomycosis is uncommon in children, those with
confirmed disease requiring systemic antifungal therapy should be
referred to a dermatologist for specialist treatment.
KEY POINT
Children with onychomycosis who may require systemic treatment should
be referred to a dermatologist.
LASER TREATMENTS IN ONYCHOMYCOSIS
In the last five years, laser systems have been developed and
introduced into the UK and the global market as a treatment for
onychomycosis. The potential effect of the laser on the invading
dermatophyte has not been fully investigated. Although it has long
been known that near-UV light frequencies have inactivated and
destroyed microbes, the effects of the various wavelengths and
energies of laser light energy have not been fully explored. Some
authors have suggested photothermal effects (light energy heats
water within tissues) destroying the fungus.47 Alternate suggestions
have been photomechanical effects – laser energy affecting
mitochondrial membranes affecting the production of redox
species, leading to the demise of the fungal cells,48 or immune-
modifying effects that ultimately inhibit or destroy fungal elements
within the nail unit.
It is often assumed that approval of laser systems in Europe
requires detailed, robust evidence of efficacy to allow them to
proceed to market. However, this is not the case. Laser systems are
licensed as medical devices, and primarily to reach market only
need to demonstrate safety whilst performance can be evaluated
on similar previously approved devices (termed ‘substantial
equivalence’). Hence, robust clinical data on their effectiveness are
not required for market approval and the vast majority of cleared
products reach the market without any supporting scientific data
and adequate evaluation.49 For lasers licensed as medical devices to
treat onychomycosis this has been the case, with clinical reports
only filtering through after they have entered the marketplace.
As a practitioner, one can often be faced with a bewildering
choice of systems and suggested capabilities. Much of the literature
available on the internet is of mixed quality, with many company
commissioned or sponsored papers that have not undergone
independent review, making the choice even more difficult. With
significant sums of investment required for a practice adopting this
technology, it is important for the practitioner to assess the
potential benefits. In addition, in offering this service to patients, it
would seem paramount to be able to give patients the best advice
on the costs and likely outcomes.
Evidence to date on the efficacy of lasers in the treatment of
onychomycosis has been reviewed (see suggested reading below).
So far, the evidence presented has been of poor methodological
quality, consisting predominantly of case series with significant
variations in equipment used, treatment regimes, laser settings and
follow-up, making basic comparisons difficult. Moreover, results
from these studies have been conflicting. More recent papers
published with longer follow-up times have discussed relapse or
deterioration of the infection at the latter stages of the study,
suggesting the effect of the laser may be temporary.50,51 To date, no
comparative trials have been published with large patient
populations, so evidence of effectiveness is still not clear.
KEY POINT
Current evidence has not shown to date any significant benefits of laser
therapies in the treatment of onychomycosis.
Of additional concern is the safe use of the devices. Training in
their use is essential to ensure patient and practitioner safety - a
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Figure 3. Nail resected to advancing edge of the fungal infection
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recent survey published a review of 50 patients who suffered
treatment errors made with laser devices in non-medical
practitioners.52 Lasers are based on the principle that they deliver
pulses of light energy through the nail that heat tissues to a high
enough temperature that can destroy pathogens, ultimately heating
the surrounding tissue and producing a plume of smoke.53 A
temperature of 55 degrees centigrade has been suggested as lethal
for fungal pathogens – heating the nail unit to this temperature
does risk severe pain for the patient and the additional risk of
tissue burns.54 Although this can be mitigated in some laser
systems by adjusting the energy dose, length of pulse, or use of
cooling sprays, the safety aspect has not been widely investigated
or addressed in current studies.
Recently, a report has been published of tissue necrosis
occurring in a diabetic patient undergoing laser treatment for
onychomycosis.55 Moreover, laser systems, as they produce smoke,
should be used with a suitable vacuum extraction system to reduce
the likelihood of inhalation of the smoke, which can contain viable
fungal elements and other pathogens that may be present in the
treatment area.56
OUTCOMES IN THE TREATMENT OF FUNGAL FOOT INFECTION
Technical success versus aesthetic failure
At the conclusion of this review, which has covered the diagnosis
and treatment of fungal foot infection, it is important to appreciate
the current issues around treatment outcomes with the disease.
Tinea pedis remains a disease that is relatively straightforward to
diagnose and, for the most part, has an effective treatment.
However, onychomycosis presents more of a challenge to the
practitioner and the sufferer alike.
The desired outcome for a patient presenting with
onychomycosis may be subtly different for the patient and
practitioner. The practitioner can see a fungal nail and can offer an
intervention that can potentially destroy the fungus causing the
infection (a ‘mycological cure’), whilst the patient is relatively
uninterested in this, and is purely seeking to restore a dystrophic
nail to its former, normal appearance (the ‘clinical cure’). Research
into the effectiveness of the treatment of onychomycosis shows a
great variability in the results, as the higher mycological cure rates
are more frequently headlined in studies over the significantly
lower clinical cure rate, giving an illusion that these interventions
are effective, albeit not to restore a normal looking nail, but to just
remove the invading fungus.
Clinical experience tells us that fungal nail infection does not
occur in healthy nails, but in nails previously traumatised –
confirming the clinical observation that most onychomycosis occurs
in the hallux and fifth nails, due to footwear trauma. Therefore,
these nails are frequently dystrophic before the infection occurs.
Successful administration of any onychomycosis treatment will
merely serve to remove the infection but leave a nail that is fungal
free but looks onychauxic. Although a mycological cure (the fungus
has gone), the patient may feel the treatment has not worked as
there is very little difference in the nail appearance afterwards (a
clinical cure failure).
The conclusion to this is that patients should be advised of the
potential outcomes of onychomycosis before undertaking any
intervention to avoid disappointment at the end of a course of
treatment.
Fungal foot infection usually returns
Despite the availability of effective antifungal agents and
successful mycological cures, studies have shown that fungal foot
infection is very likely to return.57,58 Re-exposure to fungal fomites
is inevitable from the environment, the patient’s hosiery and
footwear, causing reinfection. Therefore any intervention should
include detailed advice about preventing recurrence. Providing a
foot is clear of fungus, normally the only route to re-infection is
through the skin and, if unchecked, eventually into the nails.
Therefore, prophylactic use of anti-fungal agents should be
encouraged on a regular basis for those suffering persistent
infections.
Footwear and hosiery decontamination remains an option as
the footwear can act as a fungal reservoir, and research proving
the effectiveness of decontamination has been limited but
informative. One such study demonstrated that terbinafine as a
powder spray or solution can have rapid antifungal effects (within
48h) following a single application on infected insoles, lasting up
to 3-6 weeks.59 The use of copper oxide impregnated socks has
been shown to be effective in a single case report but remains to
be fully tested.60
KEY POINT
Whatever therapy is being implemented, fungal foot infection virtually
always returns and so measures should be taken to prevent its recurrence.
CONCLUSION
Fungal foot infection continues to be a common problem,
particularly in older adults, showing no reduction in its prevalence.
Confirmation of the diagnosis is required for any patient,
particularly if treatment is being considered for onychomycosis. A
range of treatment options is available to patients with tinea pedis
that, when used appropriately, are usually effective.
Onychomycosis remains a more significant challenge, with
topical and systemic drug agents being popular. Laser therapy
hailed as a step forward for the condition remains to produce
convincing evidence of its safety, effectiveness or cost-effectiveness
to date. Careful consideration with the patient is required before
deciding on any particular treatment. Clarity in conveying the
likely outcomes is important and it must be appreciated that, for
many patients, despite the chance of successful treatment by any
modality, reinfection over the subsequent months is a common
occurrence, so measures should be taken to prevent this from
occurring.
Figure 4. Adequate amounts of nail debris and skin must be
collected to improve mycological results
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